Premium
BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION
Author(s) -
Kim Y.H.,
Prince H.M.,
Whittaker S.,
Horwitz S.M.,
Duvic M.,
Scarisbrick J.,
Quaglino P.,
Zinzani P.L.,
Wolter P.,
Bechter O.,
Wang Y.,
PalancaWessels M.C.,
Wood K.W.,
Li M.,
Liu Y.,
Lin H.,
Little M.,
Danaee H.,
Trepicchio W.,
Dummer R.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_65
Subject(s) - cd30 , brentuximab vedotin , mycosis fungoides , medicine , biopsy , immunohistochemistry , lymphoma , oncology